Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.

Bozdag M, Ferraroni M, Ward C, Carta F, Bua S, Angeli A, Langdon SP, Kunkler IH, Al-Tamimi AS, Supuran CT.

Eur J Med Chem. 2019 Aug 7;182:111600. doi: 10.1016/j.ejmech.2019.111600. [Epub ahead of print]

PMID:
31419777
2.

Development and characterisation of acquired radioresistant breast cancer cell lines.

Gray M, Turnbull AK, Ward C, Meehan J, Martínez-Pérez C, Bonello M, Pang LY, Langdon SP, Kunkler IH, Murray A, Argyle D.

Radiat Oncol. 2019 Apr 15;14(1):64. doi: 10.1186/s13014-019-1268-2.

3.

Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment.

Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Murray A, Argyle D.

Curr Top Microbiol Immunol. 2019 Mar 12. doi: 10.1007/82_2019_159. [Epub ahead of print]

PMID:
30859401
4.

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer.

Bonello M, Sims AH, Langdon SP.

Cancer Biol Med. 2018 Nov;15(4):375-388. doi: 10.20892/j.issn.2095-3941.2018.0062.

5.

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.

Jarman EJ, Ward C, Turnbull AK, Martinez-Perez C, Meehan J, Xintaropoulou C, Sims AH, Langdon SP.

Breast Cancer Res. 2019 Jan 22;21(1):10. doi: 10.1186/s13058-019-1097-0.

6.

Biocompatibility of common implantable sensor materials in a tumor xenograft model.

Gray ME, Meehan J, Blair EO, Ward C, Langdon SP, Morrison LR, Marland JRK, Tsiamis A, Kunkler IH, Murray A, Argyle D.

J Biomed Mater Res B Appl Biomater. 2019 Jul;107(5):1620-1633. doi: 10.1002/jbm.b.34254. Epub 2018 Oct 27.

7.

Implantable biosensors and their contribution to the future of precision medicine.

Gray M, Meehan J, Ward C, Langdon SP, Kunkler IH, Murray A, Argyle D.

Vet J. 2018 Sep;239:21-29. doi: 10.1016/j.tvjl.2018.07.011. Epub 2018 Jul 29. Review.

8.

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.

Xintaropoulou C, Ward C, Wise A, Queckborner S, Turnbull A, Michie CO, Williams ARW, Rye T, Gourley C, Langdon SP.

BMC Cancer. 2018 Jun 5;18(1):636. doi: 10.1186/s12885-018-4521-4.

9.

Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness.

Ward C, Meehan J, Gray M, Kunkler IH, Langdon SP, Argyle DJ.

Metabolites. 2018 Feb 10;8(1). pii: E13. doi: 10.3390/metabo8010013. Review.

10.

NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.

Kankia IH, Khalil HS, Langdon SP, Moult PR, Bown JL, Deeni YY.

Oxid Med Cell Longev. 2017;2017:1864578. doi: 10.1155/2017/1864578. Epub 2017 Dec 19.

11.

Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells.

Meehan J, Ward C, Turnbull A, Bukowski-Wills J, Finch AJ, Jarman EJ, Xintaropoulou C, Martinez-Perez C, Gray M, Pearson M, Mullen P, Supuran CT, Carta F, Harrison DJ, Kunkler IH, Langdon SP.

Oncotarget. 2017 Jun 27;8(26):42857-42875. doi: 10.18632/oncotarget.17143.

12.

Endocrine therapy in epithelial ovarian cancer.

Langdon SP, Gourley C, Gabra H, Stanley B.

Expert Rev Anticancer Ther. 2017 Feb;17(2):109-117. doi: 10.1080/14737140.2017.1272414. Epub 2016 Dec 24. Review.

13.

Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002.

Goltsov A, Tashkandi G, Langdon SP, Harrison DJ, Bown JL.

Eur J Pharm Sci. 2017 Jan 15;97:170-181. doi: 10.1016/j.ejps.2016.11.008. Epub 2016 Nov 8.

14.

A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.

Khalil HS, Langdon SP, Goltsov A, Soininen T, Harrison DJ, Bown J, Deeni YY.

Oncotarget. 2016 Nov 15;7(46):75874-75901. doi: 10.18632/oncotarget.12425.

15.

Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models.

Martínez-Pérez C, Ward C, Turnbull AK, Mullen P, Cook G, Meehan J, Jarman EJ, Thomson PI, Campbell CJ, McPhail D, Harrison DJ, Langdon SP.

Br J Cancer. 2016 Apr 12;114(8):905-16. doi: 10.1038/bjc.2016.6. Epub 2016 Mar 31.

16.

Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.

Koussounadis A, Langdon SP, Um I, Kay C, Francis KE, Harrison DJ, Smith VA.

BMC Cancer. 2016 Mar 10;16:205. doi: 10.1186/s12885-016-2212-6.

17.

NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.

Khalil HS, Langdon SP, Kankia IH, Bown J, Deeni YY.

Oxid Med Cell Longev. 2016;2016:4148791. doi: 10.1155/2016/4148791. Epub 2015 Dec 7.

18.

The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.

Huang R, Langdon SP, Tse M, Mullen P, Um IH, Faratian D, Harrison DJ.

Oncotarget. 2016 Jan 26;7(4):4695-711. doi: 10.18632/oncotarget.6618.

19.

Multi-Scale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers.

Briffa R, Um I, Faratian D, Zhou Y, Turnbull AK, Langdon SP, Harrison DJ.

PLoS One. 2015 Dec 17;10(12):e0144708. doi: 10.1371/journal.pone.0144708. eCollection 2015.

20.

Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis.

Verleyen W, Langdon SP, Faratian D, Harrison DJ, Smith VA.

Sci Rep. 2015 Oct 27;5:15563. doi: 10.1038/srep15563.

21.

Technical innovation in adjuvant radiotherapy: Evolution and evaluation of new treatments for today and tomorrow.

Kunkler IH, Ward C, Langdon SP.

Breast. 2015 Nov;24 Suppl 2:S114-9. doi: 10.1016/j.breast.2015.07.026. Epub 2015 Oct 1. Review.

22.

A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models.

Xintaropoulou C, Ward C, Wise A, Marston H, Turnbull A, Langdon SP.

Oncotarget. 2015 Sep 22;6(28):25677-95. doi: 10.18632/oncotarget.4499.

23.

Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models.

Ward C, Meehan J, Mullen P, Supuran C, Dixon JM, Thomas JS, Winum JY, Lambin P, Dubois L, Pavathaneni NK, Jarman EJ, Renshaw L, Um IH, Kay C, Harrison DJ, Kunkler IH, Langdon SP.

Oncotarget. 2015 Sep 22;6(28):24856-70. doi: 10.18632/oncotarget.4498.

24.

Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system.

Koussounadis A, Langdon SP, Um IH, Harrison DJ, Smith VA.

Sci Rep. 2015 Jun 8;5:10775. doi: 10.1038/srep10775.

25.

Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.

Khalil HS, Goltsov A, Langdon SP, Harrison DJ, Bown J, Deeni Y.

J Biotechnol. 2015 May 20;202:12-30. doi: 10.1016/j.jbiotec.2014.09.027. Epub 2014 Nov 5.

PMID:
25449014
26.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review.

PMID:
25347767
27.

Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer.

Martinez-Perez C, Ward C, Cook G, Mullen P, McPhail D, Harrison DJ, Langdon SP.

Biochem Soc Trans. 2014 Aug;42(4):1017-23. doi: 10.1042/BST20140073. Review.

PMID:
25109996
28.

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy.

Goltsov A, Deeni Y, Khalil HS, Soininen T, Kyriakidis S, Hu H, Langdon SP, Harrison DJ, Bown J.

Cells. 2014 Jun 10;3(2):563-91. doi: 10.3390/cells3020563.

29.

Chemotherapy-induced dynamic gene expression changes in vivo are prognostic in ovarian cancer.

Koussounadis A, Langdon SP, Harrison DJ, Smith VA.

Br J Cancer. 2014 Jun 10;110(12):2975-84. doi: 10.1038/bjc.2014.258. Epub 2014 May 27.

30.

Increased STAT1 signaling in endocrine-resistant breast cancer.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP.

PLoS One. 2014 Apr 11;9(4):e94226. doi: 10.1371/journal.pone.0094226. eCollection 2014.

31.

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations.

Goltsov A, Langdon SP, Goltsov G, Harrison DJ, Bown J.

Front Oncol. 2014 Feb 5;4:13. doi: 10.3389/fonc.2014.00013. eCollection 2014.

32.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

33.

Pertuzumab for the treatment of metastatic breast cancer.

Langdon SP, Cameron DA.

Expert Rev Anticancer Ther. 2013 Aug;13(8):907-18. doi: 10.1586/14737140.2013.814419. Review.

PMID:
23984893
34.

Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer.

Argenta PA, Um I, Kay C, Harrison D, Faratian D, Sueblinvong T, Geller MA, Langdon SP.

Gynecol Oncol. 2013 Nov;131(2):368-73. doi: 10.1016/j.ygyno.2013.07.099. Epub 2013 Jul 30.

PMID:
23911795
35.

Transcript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.

Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, Faratian D, Millar RP, Langdon SP.

Endocr Relat Cancer. 2013 Feb 18;20(1):123-36. doi: 10.1530/ERC-12-0192. Print 2013 Feb.

36.

A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen.

Lebedeva G, Yamaguchi A, Langdon SP, Macleod K, Harrison DJ.

BMC Syst Biol. 2012 Nov 8;6:138. doi: 10.1186/1752-0509-6-138.

37.

New strategies for targeting the hypoxic tumour microenvironment in breast cancer.

Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, Supuran CT, Kunkler IH.

Cancer Treat Rev. 2013 Apr;39(2):171-9. doi: 10.1016/j.ctrv.2012.08.004. Epub 2012 Oct 12. Review.

PMID:
23063837
38.

Feedforward and feedback regulation of the MAPK and PI3K oscillatory circuit in breast cancer.

Hu H, Goltsov A, Bown JL, Sims AH, Langdon SP, Harrison DJ, Faratian D.

Cell Signal. 2013 Jan;25(1):26-32. doi: 10.1016/j.cellsig.2012.09.014. Epub 2012 Sep 18.

PMID:
23000339
39.

Animal modeling of cancer pathology and studying tumor response to therapy.

Langdon SP.

Curr Drug Targets. 2012 Nov;13(12):1535-47. Review.

PMID:
22974396
40.

Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines.

Winum JY, Carta F, Ward C, Mullen P, Harrison D, Langdon SP, Cecchi A, Scozzafava A, Kunkler I, Supuran CT.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4681-5. doi: 10.1016/j.bmcl.2012.05.083. Epub 2012 May 30.

PMID:
22721713
41.

Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.

Sims AH, Zweemer AJ, Nagumo Y, Faratian D, Muir M, Dodds M, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Br J Cancer. 2012 May 22;106(11):1779-89. doi: 10.1038/bjc.2012.176. Epub 2012 May 1.

42.

HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis.

McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D.

J Clin Pathol. 2012 Jul;65(7):670-1; author reply 671-2. doi: 10.1136/jclinpath-2011-200616. Epub 2012 Mar 12. No abstract available.

PMID:
22412045
43.

The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.

Ng CK, Cooke SL, Howe K, Newman S, Xian J, Temple J, Batty EM, Pole JC, Langdon SP, Edwards PA, Brenton JD.

J Pathol. 2012 Apr;226(5):703-12. doi: 10.1002/path.3980. Epub 2012 Feb 9.

PMID:
22183581
44.

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.

Lebedeva G, Sorokin A, Faratian D, Mullen P, Goltsov A, Langdon SP, Harrison DJ, Goryanin I.

Eur J Pharm Sci. 2012 Jul 16;46(4):244-58. doi: 10.1016/j.ejps.2011.10.026. Epub 2011 Nov 9.

45.

GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.

Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP, Langdon SP.

BMC Cancer. 2011 Nov 3;11:476. doi: 10.1186/1471-2407-11-476.

46.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.

Cell Signal. 2012 Feb;24(2):493-504. doi: 10.1016/j.cellsig.2011.09.030. Epub 2011 Oct 4.

PMID:
21996585
47.

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

Faratian D, Sims AH, Mullen P, Kay C, Um I, Langdon SP, Harrison DJ.

PLoS One. 2011;6(8):e23772. doi: 10.1371/journal.pone.0023772. Epub 2011 Aug 31.

48.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

Clin Cancer Res. 2011 Jul 1;17(13):4451-61. doi: 10.1158/1078-0432.CCR-10-2461. Epub 2011 May 13.

49.

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

Faratian D, Um I, Wilson DS, Mullen P, Langdon SP, Harrison DJ.

Eur J Cancer. 2011 Jun;47(9):1420-31. doi: 10.1016/j.ejca.2011.01.014. Epub 2011 Feb 18.

PMID:
21334202
50.

Compensatory effects in the PI3K/PTEN/AKT signaling network following receptor tyrosine kinase inhibition.

Goltsov A, Faratian D, Langdon SP, Bown J, Goryanin I, Harrison DJ.

Cell Signal. 2011 Feb;23(2):407-16. doi: 10.1016/j.cellsig.2010.10.011. Epub 2010 Oct 14.

PMID:
20951800

Supplemental Content

Loading ...
Support Center